The researchers showed that Cas12a discriminates strongly against mismatches to DNA targets, leading to less off-target DNA cleavage than with Cas9.
Led by researchers at the University of Iceland, the study combined deep proteomic, genomic, and phenotypic data from a cohort of more than 5,000 subjects.
A Stony Brook University-led team re-analyzed the FOXP2 gene for signs of selection using a larger, more diverse cohort, but were unable to find any.
Diet- and height-related variants were selected for in a Flores Island pygmy population, according to a study, which also provided insights into the population's history.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
Revenue gains made by the company's protein and molecular diagnostics units were offset by weak demand for its Novaprep cytology products.
Revenues from the company's diagnostics business and discovery and analytical solutions business each grew 10 percent on an organic basis.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
Exosome markets a urine-based test called ExoDx Prostate (IntelliScore) to help determine whether patients with ambiguous PSA tests needs a prostate biopsy.
The system, called EvolvR, can continuously diversify all nucleotides within a tunable window at user-defined loci using CRISPR-guided nickases.
Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.
The teams, from the Chinese Academy of Sciences and NYU Langone Health, generated viable yeast strains with just one or two chromosomes.
Single-cell RNA sequencing from mouse trachea and human bronchial epithelial cells unearthed new cell types, including ionocytes enriched for CFTR expression.
The grants are designed to help investigators working within groups pursue independent research and advance their careers in genomic science.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
In addition, Qiagen has partnered with Japan's SRL for companion diagnostic development, and its CareHPV test was added to the WHO list of prequalified IVDs.
Myriad said that it will fund the $375 million acquisition with a combination of cash, common stock, and funds from its revolving credit facility.
The firm said it will use the funds to build its IP portfolio, expand its team, and develop an infrastructure for partners to build on its CRISPR platform.
Researchers saw subway line-specific microbes on the hands of subway riders, with increased skin microbial community convergence in samples from evening commuters.
Centrillion Technologies received a multimillion US dollar investment from WeDoctor while Centrillion Technologies Taiwan obtained a strategic investment from Arm IoT Fund.
The companies will work on applying barcoding technology to single-cell measurements of gene and protein expression and to immune cell profiling.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
The company beat the consensus Wall Street estimate on the top line but missed it on the bottom line. It placed 39 net new ePlex analyzer during the quarter.
Strength in sequencing and array consumables as well as the firm's services drove second quarter revenues to $830 million, easily surpassing analyst estimates.
A panel led by the FH Foundation recommends routine genetic testing for those with very high LDL cholesterol and a family history of high cholesterol or early heart attack.
The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.
Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.
CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.
In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.